Study Finds Ayahuasca Affects Epigenetic Gene Expression
In this Gaia News special investigation, we take a look at groundbreaking new research being done on ayahuasca, an ancient psychedelic plant medicine showing great promise in addressing the most difficult to treat mental health conditions, and may even change our DNA.
Dr. Simon Ruffle is a psychiatrist and researcher who led this study conducted in the Peruvian Amazon.
“Ayahuasca is a psychedelic brew that is used in the Amazon rainforest. It’s been used for at least hundreds of years and there’s some evidence that suggests that it may have been used for thousands of years,” Ruffell said.
“It’s used for a wide variety of purposes and normally by indigenous tribes. It’s used most commonly, now, for healing. And there’s been a lot of interest from people from the West going to the Amazon rainforest in order to drink ayahuasca. And also ayahuasca is spreading all over the world and now can be found on pretty much every continent.”
Watch Part 1:
In part two we look at how researchers found a statistically significant change in the expression of the SIGMAR-1 gene which is thought to be involved with how traumatic memories are recalled.
Watch Part 2:
About the Author
Government Approval of MDMA for Treating PTSD Likely
For the millions of Americans suffering from Posttraumatic Stress Disorder (PTSD), there may finally be a solution. A late-stage clinical trial of the psychedelic drug MDMA has shown great promise in treating the condition, making FDA approval likely in the next few years.
MDMA, an illegal drug commonly known as “ecstasy” or “molly” started out as a synthetic compound created in 1912. After a period of use in the treatment of mental health conditions, it escaped in the 1980s from the clinic to the dance floor and was criminalized by the FDA. But a few proponents continue to push for research, including Dr. Rick Doblin who founded the Multidisciplinary Association for Psychedelic Studies, or MAPS.
Decades later their efforts finally led to a green light from the FDA for clinical study. Since then, there have been three rigorous clinical trials, which have all shown enormous promise of the drug in combination with psychotherapy to treat PTSD.
